Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study (Q34131807)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study (English)

1 reference

Europe PubMed Central

31 July 2017

1 reference

based on heuristic

inferred from title

object named as

Susan L Cohn

6

0 references

Katherine K Matthay

7

object named as

Katherine K Matthay

1 reference

Europe PubMed Central

31 July 2017

author name string

Wendy B London

1

1 reference

Europe PubMed Central

31 July 2017

Christopher N Frantz

2

1 reference

Europe PubMed Central

31 July 2017

Laura A Campbell

3

1 reference

Europe PubMed Central

31 July 2017

Robert C Seeger

4

1 reference

Europe PubMed Central

31 July 2017

Babette A Brumback

5

1 reference

Europe PubMed Central

31 July 2017

Robert P Castleberry

8

1 reference

Europe PubMed Central

31 July 2017

Lisa Diller

9

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

26 July 2010

1 reference

Europe PubMed Central

31 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

31 July 2017

28

1 reference

Europe PubMed Central

31 July 2017

24

1 reference

Europe PubMed Central

31 July 2017

3808-3815

1 reference

Europe PubMed Central

31 July 2017

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Factors influencing survival in children with recurrent neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

5 July 2018

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

28 October 2018

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940398

28 October 2018

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20660830

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.27.5016

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34131807&oldid=1990379466"